Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 22, 2015 11:08 PM ET

Pharmaceuticals

Company Overview of Hospira Inc.

Company Overview

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment o...

275 North Field Drive

Lake Forest, IL 60045

United States

Founded in 2003

19,000 Employees

Phone:

224-212-2000

Key Executives for Hospira Inc.

Chief Executive Officer, Director and Member of Science & Technology Committee
Age: 58
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice President of Finance
Age: 57
Total Annual Compensation: $477.4K
Senior Vice President of Operations
Age: 46
Total Annual Compensation: $464.7K
President of Hospira Medical Devices
Age: 49
Total Annual Compensation: $512.5K
Chief Scientific Officer and Senior Vice President
Age: 45
Total Annual Compensation: $550.5K
Compensation as of Fiscal Year 2014.

Hospira Inc. Key Developments

Hospira Inc., Q1 2015 Earnings Call, Apr 28, 2015

Hospira Inc., Q1 2015 Earnings Call, Apr 28, 2015

Hospira Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Hospira Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's net sales were $1,174.9 million compared with $1,050.8 million a year ago. The majority of the increase was due to continued strong net sales of Specialty Injectable Pharmaceuticals (SIP) in the United States. Income from operations was $133.4 million compared with $99.6 million a year ago. Adjusted income from operations was $247.2 million compared with $151.5 million a year ago. Income before income taxes was $121.9 million compared with $81.1 million a year ago. Net income was $75.6 million or $0.43 per diluted share compared with $67.9 million or $0.40 per diluted share a year ago. Adjusted net income was $170.1 million or $0.97 per diluted share compared with $101.7 million or $0.60 per diluted share a year ago. Net cash used in operating activities was $100.3 million compared with net cash provided by operating activities of $18.3 million a year ago. The decrease is primarily due to the upfront R&D milestone payment to Pfenex, higher employee incentive payments and higher investments in working capital. Capital expenditures (including instruments placed with or leased to customers) were $103.4 million compared with $95.1 million a year ago.

Hospira Inc. Presents at 4th Edition of Global Pharma Regulatory Summit 2015, Apr-24-2015 12:00 PM

Hospira Inc. Presents at 4th Edition of Global Pharma Regulatory Summit 2015, Apr-24-2015 12:00 PM. Venue: The Lalit, Sahar Airport Road, Mumbai - 400059, Maharashtra, India. Speakers: KS Babu, Head Regulatory.

Similar Private Companies By Industry

Company Name Region
NeilMed Pharmaceuticals, Inc. United States
ARMGO Pharma, Inc. United States
Banner Pharmacaps Inc. United States
Pharmacology Research Institute United States
Alacrity Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
February 5, 2015
--
Merger/Acquisition
September 5, 2014
Hospira Inc., Receptal Line of Products
Merger/Acquisition
August 5, 2014
TheraDoc, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hospira Inc., please visit www.hospira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.